The intersection of oncology and reproductive medicine is a rapidly evolving field, yet clinician guidance on the timing and interpretation of ORT remains inconsistent. As cancer survival rates improve, the emphasis on survivorship—specifically reproductive health—has become paramount. This study addresses a critical gap in oncofertility by providing quantitative thresholds for risk stratification. Many oncologists rely on patient age to estimate fertility risk, which often overlooks significant biological variation in ovarian reserve. By establishing AMH as a primary prognostic tool, clinicians can provide more accurate, evidence-based counseling regarding the likelihood of post-treatment menopause. This evidence is vital for justifying the costs and invasive nature of rapid-access fertility preservation (e.g., oocyte vitrification). Furthermore, understanding the limitations of FSH during the immediate post-chemotherapy recovery phase prevents premature diagnosis of infertility, allowing for realistic family planning discussions and timely referrals to reproductive specialists.
To quantify the prognostic accuracy of pre-treatment Anti-Müllerian Hormone (AMH) and Antral Follicle Count (AFC) in predicting long-term ovarian function recovery following gonadotoxic chemotherapy.
In this prospective multicenter observational study, 642 premenopausal women (mean age 29.4 ± 5.2 years) diagnosed with breast cancer, lymphoma, or gynecological malignancies were enrolled. Baseline ORT, including serum AMH, Follicle-Stimulating Hormone (FSH), and transvaginal ultrasound for AFC, was performed prior to the initiation of chemotherapy. Standardized chemotherapy regimens, predominantly involving alkylating agents (Cyclophosphamide), were documented using the Cyclophosphamide Equivalent Dose (CED). Follow-up assessments were conducted at 6, 12, and 24 months post-chemotherapy. The primary endpoint was the incidence of Premature Ovarian Insufficiency (POI), defined as amenorrhea for >12 months with FSH >40 IU/L. Secondary endpoints included the rate of AMH recovery to ≥50% of baseline. Statistical analysis employed Cox proportional hazards models and Receiver Operating Characteristic (ROC) curves to determine the Area Under the Curve (AUC) for each biomarker's predictive capacity. Multi-variate analysis adjusted for age, diagnosis, and cumulative gonadotoxic load.
Of the 642 participants, 28.5% (n=183) developed POI within 24 months of completing treatment. Baseline AMH demonstrated a higher predictive accuracy for POI (AUC 0.88; 95% CI 0.84–0.92) compared to AFC (AUC 0.74; 95% CI 0.70–0.79) and age (AUC 0.69; 95% CI 0.65–0.73). Patients with a baseline AMH <1.2 ng/mL were 5.4 times more likely to experience permanent ovarian failure (OR 5.42; 95% CI 3.1–9.5, p<0.001). At 12 months post-treatment, the median AMH level across the cohort was 0.45 ng/mL, reflecting a 72% decrease from baseline. Recovery of ovarian function was significantly correlated with lower cumulative Cyclophosphamide doses (<6g/m²; p=0.012). Interestingly, 15% of patients with undetectable AMH at 6 months post-treatment showed a partial recovery of follicle activity by 24 months, suggesting a 'dormant' phase rather than complete exhaustion. Multivariate analysis confirmed that baseline AMH (β = -0.42, p<0.001) and age (β = 0.28, p=0.004) were the strongest independent predictors of post-chemotherapy FSH levels.
Pre-treatment AMH serves as the most reliable independent predictor of ovarian reserve preservation post-chemotherapy. A baseline threshold of 1.2 ng/mL is a critical marker for identifying patients at high risk of POI. While AFC remains a useful adjunctive tool, its clinical utility is often limited by inter-operator variability and chemotherapy-induced pelvic changes. The study confirms that chronological age alone is insufficient for predicting reproductive outcomes in the oncology population. We advocate for mandatory baseline ORT for all premenopausal women prior to initiating cytotoxic therapy. These findings support the integration of individualized fertility preservation strategies into standard oncological care, ensuring that high-risk patients are prioritized for oocyte or embryo cryopreservation. Future research should focus on the development of age-specific nomograms to further refine these predictive models.